This implicated the therapeutic potential of LSD1 inhibition in combination with PARP inhibitors in HR-proficient OC patients, consistent with the results observed in vitro and in vivo tumor xenografts (Figs. 6 and 8). Here, PARP1 is linked to neoplasm.